<DOC>
	<DOCNO>NCT02718443</DOCNO>
	<brief_summary>VXM01 phase I pilot study patient operable recurrence glioblastoma examine safety , tolerability , immune biomarker response investigational VEGFR-2 DNA vaccine VXM01</brief_summary>
	<brief_title>VXM01 Phase I Pilot Study Patients With Operable Recurrence Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Written informed consent , sign date 2 . Histologically diagnosed intracranial supratentorial malignant glioma ( contrastenhancing anaplastic astrocytoma WHO Grade III glioblastoma WHO Grade IV ) . 3 . Male female patient must postmenopausal least 2 year surgically sterile . 4 . Age ≥18 year 5 . Evidence tumor progression follow least one therapy regimen must contain radiation chemotherapy temozolamid , measure MRI 6 . Candidates tumor reoperation 7 . Neurosurgical intervention postponable 30 day 8 . Laboratory result ( clinical chemistry , hematology , urine , liver enzymes , creatinine ) without clinically relevant abnormality 9 . Patients must able undergo MRI 10 . No concomitant medication dexamethasone time vaccination 11 . No active infection time vaccination 12 . Karnofsky performance status &gt; 70 13 . Appropriate hematologic parameter ( immunomonitoring ) : leukocytes ≥4.0 x 109 / L , lymphocytes ≥0.6 x 109 / L 14 . Tumor sample available pathology review , central detection Tcell responses peripheral blood tumor tissue 15 . No medical social condition may interfere study outcome followup 1 . Treatment clinical trial within 30 day screen 2 . Known positive test result Hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus antibodies 1/2 3 . Any condition treatment , opinion investigator , might interfere study current drug substance abuse 4 . Inability understand protocol requirement , instruction studyrelated restriction , nature , scope , possible consequence study 5 . Unlikely comply protocol requirement , instruction studyrelated restriction ; e.g. , uncooperative attitude , inability return followup visit , improbability complete study 6 . Pregnancy breast feed 7 . Positive antityphoid IgG/IgM antibody accord onsite test Day 0 8 . Cardiovascular disease define : Uncontrolled hypertension ( systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg ) Arterial thromboembolic event within 6 month randomization include : Myocardial infarction Unstable angina pectoris Cerebrovascular accident Transient ischemic attack 9 . Congestive heart failure New York Heart Association grade III IV 10 . Serious ventricular arrhythmia require medication 11 . Clinically significant peripheral artery disease &gt; grade 2b accord Fontaine 12 . Intracranial ischemic stroke within 6 month randomization 13 . History intracranial hemorrhage 14 . Hemoptysis within 6 month randomization 15 . Esophageal varix 16 . Upper low gastrointestinal bleeding within 6 month inclusion ( Day 0 ) 17 . Significant traumatic injury surgery within 4 week randomization 18 . Nonhealing wound , incomplete wound healing , bone fracture history gastrointestinal ulcer within three year inclusion , positive gastroscopy within 3 month inclusion 19 . Gastrointestinal fistula 20 . Thrombolysis therapy within 4 week randomization 21 . Presence acute chronic systemic infection 22 . Major surgical procedure , open biopsy within 4 week randomization 23 . Chronic concurrent therapy within 2 week treatment period Day 35 : Corticosteroids ( except steroid adrenal failure emesis prophylaxis 4 mg daily dose ) immunosuppressive agent Antibiotics Bevacizumab Any cancer antiangiogenic treatment 24 . Chemotherapy screen reoperation ( Day 35 ) 25 . Known multidrug resistant gramnegative germ 26 . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation study result render patient high risk treatment complication 27 . Women childbearing potential 28 . Any condition result undue risk patient study participation accord investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>